Page 163 - Drug Class Review

Drug Effectiveness Review Project
90.0%
4.4%
total
76.1
67.5

placebo
91.3%
4.8%
62.7
NR

Alzheimer classification: Moderate-severe
Authors and Year: Reisberg et al. 2003; Rive et al. 2004; Doody et al. 2004
5.6% 3.9% 7.9 NR Primary Outcome Measures: CIBIC-Plus; ADCS-ADL modified for severe dementia (ADCS-ADLsev) Secondary Outcome Measures: SIB; MMSE; GDS; FAST; NPI; Resource Utilization in Dementia; G2 Timing of assessments: Baseline and weeks 12 and 28 MEM patients had significantly less deterioration on ADCS/ADL (difference 2.1; P = 0.02) Caregivers spent significantly less time (45.8 hours/mo) with patients receiving MEM (P = 0.01) FAST (P = 0.02) was significantly less deteriorated for MEM patients No significant differences in GDS between plac
Groups similar at baseline: Yes
memantine NR 72 88.9% 4.0% 7.1% NR Health Outcome Measures: No significant differences in NPI Intermediate Outcome Measures: No significant differences in MMSE Single item analysis of the ADL scales: (P < 0.05 for all 3)

scale • • • • • • • • • • •

Final Report Update 1 POPULATION CHARACTERISTICS: Mean age (years): Sex (% female): Ethnicity: White • Black • Other • Other germane population qualities: MMSE score • OUTCOME ASSESSMENT: RESULTS: Alzheimer's Drugs